Dexamethasone Patent Expiration
Dexamethasone is Used for treating eye conditions such as diabetic macular edema, macular edema, non-infectious uveitis, and uveitis by delivering an ocular implant. It was first introduced by Merck And Co Inc
Dexamethasone Patents
Given below is the list of patents protecting Dexamethasone, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Dextenza | US12144889 | Methods of treating allergic conjunctivitis | Apr 26, 2041 | Ocular Therapeutix |
Dexycu Kit | US11097061 | Systems, kits and methods for loading and delivering a small volume dose from a syringe | Jun 23, 2039 | Eyepoint Pharms |
Hemady | US10537585 | Compositions comprising dexamethasone | Dec 18, 2037 | Dexcel |
Hemady | US11304961 | Compositions comprising dexamethasone | Dec 18, 2037 | Dexcel |
Dextenza | US11458041 | Punctal plug and bioadhesives | Nov 16, 2037 | Ocular Therapeutix |
Dextenza | US12150896 | Punctal plug and bioadhesives | Oct 07, 2036 | Ocular Therapeutix |
Dexycu Kit | US10022502 | Dose guides for injection syringe | Jun 22, 2034 | Eyepoint Pharms |
Dexycu Kit | US10028965 | Use of sustained release dexamethasone in post-cataract surgery inflammation | May 23, 2034 | Eyepoint Pharms |
Dexycu Kit | US10159683 | Use of sustained release dexamethasone in post-cataract surgery inflammation | May 23, 2034 | Eyepoint Pharms |
Dexycu Kit | US10799642 | Dose guides for injection syringe | May 11, 2032 | Eyepoint Pharms |
Dextenza | US8409606 | Drug delivery through hydrogel plugs | May 14, 2030 | Ocular Therapeutix |
Dextenza | US8563027 | Drug delivery through hydrogel plugs | Feb 12, 2030 | Ocular Therapeutix |
Dextenza | US9254267 | Composite hydrogel drug delivery systems |
Sep 11, 2024
(Expired) | Ocular Therapeutix |
Ozurdex | US6899717 | Methods and apparatus for delivery of ocular implants |
Nov 01, 2023
(Expired) | Abbvie |
Dexycu Kit | US6960346 | Vehicles for delivery of biologically active substances |
Jul 03, 2023
(Expired) | Eyepoint Pharms |
Ozurdex | US10076526 | Ocular implant made by a double extrusion process |
Jan 09, 2023
(Expired) | Abbvie |
Ozurdex | US10702539 | Ocular implant made by a double extrusion process |
Jan 09, 2023
(Expired) | Abbvie |
Ozurdex | US8034366 | Ocular implant made by a double extrusion process |
Jan 09, 2023
(Expired) | Abbvie |
Ozurdex | US8034370 | Ocular implant made by a double extrusion process |
Jan 09, 2023
(Expired) | Abbvie |
Ozurdex | US8506987 | Ocular implant made by a double extrusion process |
Jan 09, 2023
(Expired) | Abbvie |
Ozurdex | US9192511 | Ocular implant made by a double extrusion process |
Jan 09, 2023
(Expired) | Abbvie |
Dexycu Kit | US7560120 | Vehicles for delivery of biologically active substances |
Sep 05, 2022
(Expired) | Eyepoint Pharms |
Ozurdex | US7767223 | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use |
Nov 28, 2021
(Expired) | Abbvie |
Ozurdex | US6726918 | Methods for treating inflammation-mediated conditions of the eye |
Oct 20, 2020
(Expired) | Abbvie |
Ozurdex | US7033605 | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
Oct 20, 2020
(Expired) | Abbvie |
Ozurdex | US8043628 | Methods for reducing edema |
Oct 20, 2020
(Expired) | Abbvie |
Ozurdex | US8063031 | Implants and methods for treating inflammation-mediated conditions of the eye |
Oct 20, 2020
(Expired) | Abbvie |
Ozurdex | US8088407 | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
Oct 20, 2020
(Expired) | Abbvie |
Ozurdex | US9012437 | Implants and methods for treating inflammation-mediated conditions of the eye |
Oct 20, 2020
(Expired) | Abbvie |
Ozurdex | US9283178 | Methods for treating edema in the eye and intraocular implants for use therefor |
Oct 20, 2020
(Expired) | Abbvie |
Ozurdex | US9592242 | Methods for treating edema in the eye and intraocular implants for use therefor |
Oct 20, 2020
(Expired) | Abbvie |
Ozurdex | US9775849 | Implants and methods for treating inflammation-mediated conditions of the eye |
Oct 20, 2020
(Expired) | Abbvie |
Dexamethasone's Family Patents
